{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-300388","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.044093+00:00","generated_at":"2026-06-07T09:09:40.591254+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shattuck reports early efficacy for SL-172154 in frontline HR-MDS and TP53m AML","bullets":["HR-MDS: 5/14 evaluable patients achieved CR; 4 achieved mCR with hematologic improvement.","TP53m AML: 2/11 evaluable patients achieved CR; 1 patient with CRi proceeded to allo-HCT.","Grade 3/4 AEs related to SL-172154 reported in 14% of TP53m AML and 18% of HR-MDS patients.","Infusion-related reactions most common TEAE; no destructive anemia observed.","Cohorts expanded; additional data expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-300388","json":"https://secwatch.observer/filing/0001193125-23-300388.json","markdown":"https://secwatch.observer/filing/0001193125-23-300388.md","text":"https://secwatch.observer/filing/0001193125-23-300388.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312523300388/0001193125-23-300388-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312523300388/d14784d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:09:40.591254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}